Ultomiris is a Intravenous Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Alexion Pharmaceuticals Inc.. The primary component is Ravulizumab.
| Product ID | 25682-028_0584968e-282e-4a10-aa66-f0329d41f571 |
| NDC | 25682-028 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Ultomiris |
| Generic Name | Ravulizumab |
| Dosage Form | Solution, Concentrate |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2018-12-21 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761108 |
| Labeler Name | Alexion Pharmaceuticals Inc. |
| Substance Name | RAVULIZUMAB |
| Active Ingredient Strength | 1100 mg/11mL |
| Pharm Classes | Complement Inhibitor [EPC],Complement Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2018-12-21 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 25682-022 | Ultomiris | ravulizumab |
| 25682-025 | Ultomiris | ravulizumab |
| 25682-028 | Ultomiris | ravulizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ULTOMIRIS 87713118 5716901 Live/Registered |
Alexion Pharmaceuticals, Inc. 2017-12-08 |